Track topics on Twitter Track topics that are important to you
VeraLight, Inc., established in 2004 as an independent spinout of InLight Solutions, is applying its proprietary Spectroscopic Advanced Glycation Endproduct (SAGE) detection technology to develop the SCOUT DS system -- intended to be the first non-invasive diabetes screening system that provides healthcare professionals with an accurate and convenient method for detecting type 2 diabetes and pre-diabetes based on the presence of advanced glycation endproduct biomarkers found in skin. Weighing about 10 pounds, the SCOUT DS is designed to be a simple-to-use device that requires no blood draw, no fasting and no waiting for a lab result. For more information see http://www.veralight.com.
VeraLight, Inc., established in 2004 as an independent spinout of InLight Solutions, is applying its proprietary Spectroscopic Advanced Glycation Endproduct (SAGE) detection technology to develop ...
We have published hundreds of VeraLight, Inc. news stories on BioPortfolio along with dozens of VeraLight, Inc. Clinical Trials and PubMed Articles about VeraLight, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of VeraLight, Inc. Companies in our database. You can also find out about relevant VeraLight, Inc. Drugs and Medications on this site too.
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...